All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
What data are expected this year within the field of CAR T for multiple myeloma?
During the 2nd European CAR T Cell Meeting in Sitges, ES, the Multiple Myeloma Hub was delighted to speak to Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR. We asked: What data are expected this year within the field of CAR T for multiple myeloma?
Mohamad Mohty discusses CAR T-cell therapy in multiple myeloma, he explains that there is an unmet need for treatment, especially in the relapsed/refractory setting. He discusses clinical trials such as CARTITUDE, bb2121, and Legend trials, that evaluated response rates and outcomes in patients with multiple myeloma that were treated with CAR T and explains the results are encouraging.
What data are expected this year within the field of CAR T for multiple myeloma?
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?